ArticleLeukemia2011
Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.
Article in Leukemia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Delayed B-cell reconstitution in the bone marrow precedes the development of chronic graft-versus-host disease following pediatric hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- Acute lymphoblastic leukemia in children and SALL4 and BMI-1 gene expression.Pediatric research · 2023Article
- Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340.Molecular cancer · 2020Article
- B cells in chronic graft-versus-host disease.Human immunology · 2019Review
- Targeting Leukemia Stem Cells in the Bone Marrow Niche.Biomedicines · 2018Review
- Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia.BMC cancer · 2017Article
- Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Frontiers in immunology · 2017Review
- The roles of Polycomb group proteins in hematopoietic stem cells and hematological malignancies.International journal of hematology · 2016Review
- Knockdown of Sall4 inhibits intrahepatic cholangiocarcinoma cell migration and invasion in ICC-9810 cells.OncoTargets and therapy · 2016Article
- The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.Blood · 2015Review
- Article
- Allogeneic stem cell transplantation for chronic myeloid leukemia.Current hematologic malignancy reports · 2013Review
- Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms.Leukemia · 2013Review
- The differential expression pattern of the BMI-1, SALL4 and ABCA3 genes in myeloid leukemia.Cancer cell international · 2012Article
- Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.Leukemia · 2012Review
- Antigens in chronic myeloid leukemia: implications for vaccine development.Cancer immunology, immunotherapy : CII · 2011Review
- Utility of BMI-1 and NANOG expression levels in survival prediction of pediatric acute lymphoblastic leukemia.Hematology, transfusion and cell therapyArticle
- Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
BMI-1 and EZH2 are polycomb group (PcG) proteins that maintain self-renewal of stem cells, and are overexpressed in leukemia. To investigate the potential of PcG proteins as leukemia-associated antigens, and as targets for graft-versus-leukemia (GVL) effects, we studied cells obtained from 86 patients with chronic myeloid leukemia (CML) and 25 human leukocyte antigen (HLA)-A*0201(+) sibling donors collected before allogeneic stem cell transplantation (SCT). Although BMI-1 overexpression in CD34(+) cells of CML patients treated with pharmacotherapy is associated with poor prognosis, we found, conversely, that in CML patients treated with SCT, a higher expression of BMI-1, and correspondingly a lower expression of its target for repression, CDKN2A, is associated with improved leukemia-free survival. Cytotoxic T-lymphocyte (CTL) responses to the BMI-1 peptide were detected in 5 of 25 (20%) donors, and in 8 of 19 (42%) HLA-A*0201(+) CML patients. BMI-1 generated more total and high-avidity immune responses, and was more immunogenic than EZH2. PcG-specific CTLs had a memory phenotype, were readily expanded in short-term cultures and were detected after SCT in recipients of PcG-specific CTL-positive donors. A higher BMI-1 expression in CML CD34(+) progenitors was associated with native BMI-1 immune responses. These immune responses to PcG proteins may target leukemia stem cells and have relevance for disease control by GVL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.